Follow the entities shaping the evidence.

…analyzed across multiple timepoints to resolve kinetics.Results Nivolumab induced three distinct response kinetics across the CRC patient…

…er tumor necrosis induced by TATE could enhance the efficacy of pembrolizumab (pembro).Methods Subjects with mCRC-MSS who had progressed on 2…

…nter. Patients received either nivolumab + ipilimumab (n=21) or pembrolizumab monotherapy (n=31). Radiological responses were assessed using …

…nuclear cells (PBMCs) were collected from NHL patients prior to NKX019 infusion. Single cell transcriptome and paired TCR sequencing w…

…ing.Conclusions Preliminary dose escalation data are promising. BI-1910 monotherapy shows a favorable safety and tolerability profile, …

…tinal toxicity, which constrains dose escalation and efficacy.2 A2B395 is an allogeneic, logic-gated, EGFR-targeted, Tmod CAR T therap…

…Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, et al. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibil…

…7), as of 28Feb2025, 29 patients with CPI-R/R melanoma received pembrolizumab (400 mg IV Q6W) plus mRNA-4359 (400 µg [n=14] or 1000 µg [n=15]…

…orm. Under US-IT each tumor mass was treated on day 0 (D0) with liposomal doxorubicin, oxaliplatin, and combretastatin A4 Phosphate (CA4P) (0.125 mg,…

…-2R targeting to be significantly augmented by combination with Entinostat. These effects are associated with TCRVβ13/IL-2R targeting augm…

… approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital (Protocol #:2004N000228).…

…ting safety and preliminary efficacy of intravenous delivery of ATTR-01 in patients with selected epithelial tumors expressing high lev…